Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Piper Sandler in a research report issued on Tuesday,Benzinga reports. They currently have ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Thank you for standing by. My name is Briana, and I will be your conference operator today. At this time, I’d like to welcome everyone to ...

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

We recently compiled a list of the 10 AI News You Shouldn’t Miss. In this article, we are going to take a look at where ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2024 investor letter. A copy ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Tempus AI (TEM) to $70 from $40 and keeps a Neutral rating on ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.